Cello Health logo

CLL - Cello Health Share Price

161p 0.0  0.0%

Last Trade - 10/08/20

Sector
Consumer Cyclicals
Size
Small Cap
Market Cap £171.0m
Enterprise Value £174.6m
Revenue £166.8m
Position in Universe th / 1806
Bullish
Bearish
Unlock CLL Revenue
Momentum
Relative Strength (%)
1m -0.72%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -2.42%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
169.9 156.7 165.3 170.3 158.9 166.8 160.9 167.4 -0.4%
-19.1 +24.6 -21.1 +61.0 -0.6 -8.0 +23.0 +5.43
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2019, Cello Health PLC revenues increased 5% to £166.8M. Net income before extraordinary items decreased 34% to £4.8M. Revenues reflect Cello Health segment increase of 9% to £96.3M, Cello Signal segment increase of 1% to £70.3M, United States segment increase of 31% to £61.1M. Net income was offset by Cello Signal segment income decrease of 29% to £2.7M.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for CLL
Graphical History

Revenue

CLL Revenue Unlock CLL Revenue

Net Income

CLL Net Income Unlock CLL Revenue

Normalised EPS

CLL Normalised EPS Unlock CLL Revenue

PE Ratio Range

CLL PE Ratio Range Unlock CLL Revenue

Dividend Yield Range

CLL Dividend Yield Range Unlock CLL Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
CLL EPS Forecasts Unlock CLL Revenue
Profile Summary

Cello Health plc, formerly Cello Group plc, is a United Kingdom-based healthcare and consumer strategic marketing company. The Company is engaged in providing market research, consulting and direct marketing services. The Company provides a range of biotech, diagnostics, devices and other non-healthcare clients. The Company operates through two segments: Cello Health and Cello Signal. The Cello Health Division provides market research, consulting and communications services principally to the Company's pharmaceutical and healthcare clients. The Cello Signal Division provides market research and direct communications services to the Company's consumer facing clients. The Company delivers its services from office networks in the United Kingdom, the United States and Singapore.

Directors
Last Annual December 31st, 2019
Last Interim December 31st, 2019
Incorporated May 5, 2004
Public Since November 9, 2004
No. of Shareholders: n/a
No. of Employees: 948
Sector Consumer Cyclicals
Industry Media & Publishing
Index
Exchange London Stock Exchange
Shares in Issue 106,230,196
Free Float (0.0%)
Eligible for
ISAs
SIPPs
CLL Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for CLL
Upcoming Events for CLL
Frequently Asked Questions for Cello Health
What is the Cello Health share price?

As of 10/08/20, shares in Cello Health are trading at 161p, giving the company a market capitalisation of £171.0m. This share price information is delayed by 15 minutes.

How has the Cello Health share price performed this year?

Shares in Cello Health are currently trading at 161p and the price has moved by 26.27% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Cello Health price has moved by 50.45% over the past year.

What are the analyst and broker recommendations for Cello Health?

Of the analysts with advisory recommendations for Cello Health, there are there are currently 0 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Cello Health is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Cello Health next release its financial results?

Cello Health is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2020-12-31
What is the Cello Health dividend yield?

The Cello Health dividend yield is 0.71% based on the trailing twelve month period.

Does Cello Health pay a dividend?

Last year, Cello Health paid a total dividend of 0.01, and it currently has a trailing dividend yield of 0.71%. Looking ahead, Cello Health has not announced an ex-dividend date yet.

When does Cello Health next pay dividends?

Cello Health has yet to annouce their ex-dividend date. The historic dividend yield on Cello Health shares is currently 0.71%.

How do I buy Cello Health shares?

To buy shares in Cello Health you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Cello Health?

Shares in Cello Health are currently trading at 161p, giving the company a market capitalisation of £171.0m.

Where are Cello Health shares listed? Where are Cello Health shares listed?

Here are the trading details for Cello Health:

Country of listing: United Kingdom
Exchange: LSE
Ticker Symbol: CLL
What kind of share is Cello Health?

We were not able to load our ranking data for Cello Health

Is there a Cello Health share price forecast 2020?

Shares in Cello Health are currently priced at 161p. At that level they are trading at 25.47% premium to the analyst consensus target price of 128.32.

Analysts covering Cello Health currently have a consensus Earnings Per Share (EPS) forecast of 0.09419 for the next financial year.

How can I tell whether the Cello Health share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cello Health. Over the past six months, the relative strength of its shares against the market has been -9.22%. At the current price of 161p, shares in Cello Health are trading at 22.73% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Cello Health PE Ratio?

The Cello Health PE ratio based on its reported earnings over the past 12 months is 21.03. The shares are currently trading at 161p.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Cello Health?

We were unable to find the directors for Cello Health.

Who are the major shareholders of Cello Health?

Here are the top five shareholders of Cello Health based on the size of their shareholding:

Liontrust Asset Management PLC Investment Advisor/Hedge Fund
Percentage owned: 10.93% (12.1m shares)
Liontrust UK Smaller Companies Fund Mutual Fund
Percentage owned: 9.25% (10.3m shares)
Ennismore Fund Management Ltd. Investment Advisor/Hedge Fund
Percentage owned: 8.48% (9.42m shares)
Ennismore European Smaller Companies Fund Mutual Fund
Percentage owned: 7.29% (8.10m shares)
J.P. Morgan Securities plc Research Firm
Percentage owned: 6.77% (7.52m shares)
Similar to CLL
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.